Biolegend, 565604, Biotinylated Recombinant Human PD-L2-Fc Chimera (carrier-free), 25μg

PD-L2 is a type I transmembrane protein of 273 amino acids, and it is a member of the B7 family. Human PD-L2 has 70% amino acid identity to its mouse orthologue. PD-L2 is the second ligand for PD-1, and its binding to PD-1 leads to the inhibition of T cell receptor–mediated lymphocyte proliferation and cytokine secretion. PD-L2/PD-1 interaction suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance. Antibody blocking of PD-L2 on dendritic cells results in enhanced T cell proliferation and cytokine production. Interaction of PD-1 by PD-L1-Ig or PD-L2-Ig fusion protein has an inhibitory effect on proliferation and cytokine production during anti-CD3-mediated stimulation. PD-L2 is expressed in biopsies from human asthmatics and lungs of aeroallergen-treated mice and its expression correlates with the asthma severity. In vivo blockade of PD-L2 reduces the severity of allergen-driven airway hyperresponsiveness (AHR).  Blockage of PD-L2 induces the IL-12 production by DC; IL-12 may limit the severity of allergen-induced AHR antagonizing IL-13. In addition, blockade of PD-1 does not have effect on AHR; therefore, PD-L2 controls asthma severity in a PD-1 independent manner. PD-L2 binds to a second receptor, RGMb (repulsive guidance molecule b) which is expressed in lung interstitial macrophages and alveolar epithelial cells and is a co-receptor for bone morphogenetic proteins BMP2/4. Blockade of the RGMb/PD-L2 interaction significantly impaired the development of respiratory tolerance since the initial T cell expansion is inhibited.
25μg
Source: Human PD-L2, amino acid (Leu20-Pro219) (Accession # Q9BQ51.2), with a linker (SRIEG), a C-terminal human IgG1 (Pro100-Lys330) and an Avi-tag, was expressed in CHO cells. Human PD-L2-Avi tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass: The 453 amino acid recombinant protein has a predicted molecular mass of approximately 50.97 kD. The DTT-reduced and non-reduced protein migrate at approximately 65 – 80 kD and 140 – 160 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Leu.
Purity: > 95%, as determined by Coomassie-stained SDS-PAGE
Formulation: 0.22 µm filtered protein solution is in PBS, 5% Glycerol
Endotoxin Level: Less than 0.1 EU per µg cytokine as determined by the LAL method
Concentration: 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity: When recombinant human PD-1 (Cat. No. 785106) is immobilized at 1 µg/mL, biotinylated recombinant human PD-L2 binds in a dose-dependent manner with ED50 range of 1 – 6 ng/mL. HRP-Avidin (Cat. No. 405103) was used to detect the binding.
Application: Bioassay
Application Notes: BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Structure: Dimer
Distribution: Immature dendritic cells, mature dendritic cells, subset of macrophages, placental endothelium, and medullary thymic epithelial cells
Function: Inhibits T cell mediated proliferation and cytokine production by CD4+ T cells, and regulates T cell responses. PD-L2 expression is up-regulated on antigen-presenting cells by IFNγ.
Interaction: Fibroblast growth factor receptors (FGFRs)
Ligand/Receptor: PD-1 (CD279), RGMb
Bioactivity: Biotinylated recombinant human PD-L2 binds to immobilized recombinant human PD-1 in a dose-dependent manner.
Biology Area: Costimulatory Molecules, Immunology
Molecular Family: CD Molecules, Immune Checkpoint Receptors, Soluble Receptors
Antigen References: Latchman Y, et al. 2001. Nat Immunol. 2:261-8 Brown JA, et al. 2003. J Immunol. 170:1257-66. Youngnak P, et al. 2003. Biochem Biophys Res Commun. 307:672-7. Singh AK, et al. 2011. Allergy. 66:155-62. Lewkowich IP, et al. 2013. Mucosal Immunol. 6:728-39. Xiao Y, et al. 2014. J Exp Med. 211:943-59. Bardhan K, et al. 2016. Front Immunol. 7:550.
Gene ID: 80380
UniProt: View information about PD-L2 on UniProt.org
Regulatory Status: RUO
Other Names: CD273, Programmed cell death 1 ligand 2 (PD-L2), B7 dendritic cellmolecule (B7-DC), Butyrophilin B7-DC, PDCD1 Ligand 2